Geron Net Income
| GERN Stock | USD 1.62 0.01 0.62% |
As of the 10th of February, Geron retains the Risk Adjusted Performance of 0.1534, downside deviation of 3.06, and Market Risk Adjusted Performance of 0.3163. Geron technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Geron Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 4.2459 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -157.1 M | -149.3 M | |
| Net Loss | -157.1 M | -149.3 M | |
| Net Loss | -127.7 M | -121.3 M | |
| Net Loss | (0.24) | (0.26) | |
| Net Income Per E B T | 1.03 | 1.12 |
Geron | Net Income | Build AI portfolio with Geron Stock |
Evaluating Geron's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Geron's fundamental strength.
Latest Geron's Net Income Growth Pattern
Below is the plot of the Net Income of Geron over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Geron financial statement analysis. It represents the amount of money remaining after all of Geron operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Geron's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Geron's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (174.57 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Geron Net Income Regression Statistics
| Arithmetic Mean | (82,185,933) | |
| Geometric Mean | 43,043,693 | |
| Coefficient Of Variation | (74.05) | |
| Mean Deviation | 52,310,274 | |
| Median | (68,881,000) | |
| Standard Deviation | 60,856,175 | |
| Sample Variance | 3703.5T | |
| Range | 184.2M | |
| R-Value | (0.77) | |
| Mean Square Error | 1597.9T | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | (9,299,961) | |
| Total Sum of Squares | 59255.6T |
Geron Net Income History
Other Fundumenentals of Geron
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Geron Net Income component correlations
Geron Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Geron is extremely important. It helps to project a fair market value of Geron Stock properly, considering its historical fundamentals such as Net Income. Since Geron's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Geron's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Geron's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Geron diversify its offerings? Factors like these will boost the valuation of Geron. Market participants price Geron higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Geron data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
Understanding Geron requires distinguishing between market price and book value, where the latter reflects Geron's accounting equity. The concept of intrinsic value - what Geron's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Geron's price substantially above or below its fundamental value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Geron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Geron 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Geron's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Geron.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Geron on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Geron or generate 0.0% return on investment in Geron over 90 days. Geron is related to or competes with Day One, Rezolute, Arvinas, Valneva SE, Tyra Biosciences, Vir Biotechnology, and Savara. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of ... More
Geron Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Geron's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Geron upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.06 | |||
| Information Ratio | 0.1566 | |||
| Maximum Drawdown | 16.99 | |||
| Value At Risk | (3.70) | |||
| Potential Upside | 7.76 |
Geron Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Geron's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Geron's standard deviation. In reality, there are many statistical measures that can use Geron historical prices to predict the future Geron's volatility.| Risk Adjusted Performance | 0.1534 | |||
| Jensen Alpha | 0.48 | |||
| Total Risk Alpha | 0.2784 | |||
| Sortino Ratio | 0.1876 | |||
| Treynor Ratio | 0.3063 |
Geron February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1534 | |||
| Market Risk Adjusted Performance | 0.3163 | |||
| Mean Deviation | 2.8 | |||
| Semi Deviation | 2.48 | |||
| Downside Deviation | 3.06 | |||
| Coefficient Of Variation | 550.06 | |||
| Standard Deviation | 3.67 | |||
| Variance | 13.47 | |||
| Information Ratio | 0.1566 | |||
| Jensen Alpha | 0.48 | |||
| Total Risk Alpha | 0.2784 | |||
| Sortino Ratio | 0.1876 | |||
| Treynor Ratio | 0.3063 | |||
| Maximum Drawdown | 16.99 | |||
| Value At Risk | (3.70) | |||
| Potential Upside | 7.76 | |||
| Downside Variance | 9.39 | |||
| Semi Variance | 6.17 | |||
| Expected Short fall | (3.85) | |||
| Skewness | 0.5802 | |||
| Kurtosis | 1.14 |
Geron Backtested Returns
Geron appears to be very risky, given 3 months investment horizon. Geron holds Efficiency (Sharpe) Ratio of 0.14, which attests that the entity had a 0.14 % return per unit of risk over the last 3 months. By evaluating Geron's technical indicators, you can evaluate if the expected return of 0.51% is justified by implied risk. Please utilize Geron's Downside Deviation of 3.06, market risk adjusted performance of 0.3163, and Risk Adjusted Performance of 0.1534 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Geron holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of 2.15, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Geron will likely underperform. Please check Geron's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Geron's current trending patterns will revert.
Auto-correlation | 0.63 |
Good predictability
Geron has good predictability. Overlapping area represents the amount of predictability between Geron time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Geron price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Geron price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Geron Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Geron reported net income of (174.57 Million). This is 151.15% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 130.57% higher than that of the company.
Geron Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Geron's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Geron could also be used in its relative valuation, which is a method of valuing Geron by comparing valuation metrics of similar companies.Geron is currently under evaluation in net income category among its peers.
Geron Current Valuation Drivers
We derive many important indicators used in calculating different scores of Geron from analyzing Geron's financial statements. These drivers represent accounts that assess Geron's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Geron's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 431.6M | 399.7M | 921.5M | 1.2B | 1.1B | 1.1B | |
| Enterprise Value | 451.4M | 419.8M | 920.4M | 1.2B | 1.1B | 1.2B |
Geron Institutional Holders
Institutional Holdings refers to the ownership stake in Geron that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Geron's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Geron's value.| Shares | Citadel Advisors Llc | 2025-06-30 | 12 M | Ubs Group Ag | 2025-06-30 | 11.7 M | Goldman Sachs Group Inc | 2025-06-30 | 9.8 M | Point72 Asset Management, L.p. | 2025-06-30 | 9.6 M | Woodline Partners Lp | 2025-06-30 | 8 M | Eversept Partners, Llc | 2025-06-30 | 7.3 M | Segall Bryant & Hamill | 2025-06-30 | 7.2 M | Aberdeen Group Plc | 2025-06-30 | 7 M | Stempoint Capital Lp | 2025-06-30 | 6.6 M | Ra Capital Management, Llc | 2025-06-30 | 60.4 M | Blackrock Inc | 2025-06-30 | 50 M |
Geron Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.0779 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 778.71 M | ||||
| Shares Outstanding | 638.36 M | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 80.97 % | ||||
| Number Of Shares Shorted | 70.45 M | ||||
| Price To Earning | (12.48) X | ||||
| Price To Book | 4.17 X | ||||
| Price To Sales | 5.64 X | ||||
| Revenue | 76.99 M | ||||
| Gross Profit | 97.86 M | ||||
| EBITDA | (154.85 M) | ||||
| Net Income | (174.57 M) | ||||
| Cash And Equivalents | 219.29 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 121.72 M | ||||
| Debt To Equity | 0.39 % | ||||
| Current Ratio | 4.85 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (218.62 M) | ||||
| Short Ratio | 5.57 X | ||||
| Earnings Per Share | (0.12) X | ||||
| Price To Earnings To Growth | (2.38) X | ||||
| Target Price | 3.4 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.62 | ||||
| Market Capitalization | 1.03 B | ||||
| Total Asset | 593.78 M | ||||
| Retained Earnings | (1.77 B) | ||||
| Working Capital | 402.69 M | ||||
| Current Asset | 115.89 M | ||||
| Current Liabilities | 6.63 M | ||||
| Net Asset | 593.78 M |
About Geron Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Geron's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Geron using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Geron based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Geron
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Geron position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Geron will appreciate offsetting losses from the drop in the long position's value.Moving together with Geron Stock
Moving against Geron Stock
| 0.83 | IMRN | Immuron Ltd ADR | PairCorr |
| 0.79 | ABP | Abpro Holdings Buyout Trend | PairCorr |
| 0.77 | GNLX | Genelux Common | PairCorr |
| 0.74 | EDIT | Editas Medicine | PairCorr |
| 0.68 | QSI | QuantumSi | PairCorr |
The ability to find closely correlated positions to Geron could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Geron when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Geron - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Geron to buy it.
The correlation of Geron is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Geron moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Geron moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Geron can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Will Biotechnology sector continue expanding? Could Geron diversify its offerings? Factors like these will boost the valuation of Geron. Market participants price Geron higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Geron data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
Understanding Geron requires distinguishing between market price and book value, where the latter reflects Geron's accounting equity. The concept of intrinsic value - what Geron's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Geron's price substantially above or below its fundamental value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Geron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.